Overview
Condor Software provides a cloud-based financial intelligence platform for biopharma, MedTech, and CROs that unifies clinical, operational, and financial data into a single source of truth for trial finances. It works by connecting to ERP and CTMS systems and automating processes such as clinical accruals, financial planning and forecasting, vendor management, and audits through its Copilot, Compass, and Connect products, giving teams real-time visibility into R&D spend. The company differentiates itself by targeting life sciences finance at scale with a dedicated SaaS platform that integrates multiple systems and delivers measurable outcomes like forecast accuracy and faster month-end closes. Its goal is to streamline fragmented clinical development finances, reduce manual work, ensure compliance, and speed up data-driven decisions in drug development.
Work here?Claim your company
Simplify's take
What believers are saying
- Condor reported over $19 billion managed R&D spend and strong product adoption in 2026.
- Five open roles on November 7, 2026 show hiring momentum despite broader biotech caution.
- Its October 2026 AI agent and grants intelligence deepen switching costs across forecasting and reconciliation.
What critics are saying
- SAP, Workday, and Veeva can copy clinical-finance workflows into existing enterprise suites by 2027.
- Biopharma budget tightening hits discretionary software first, pressuring Condor’s expansion sales cycle into 2027.
- Customer concentration risk stays acute if Acadia, BridgeBio, or Madrigal standardize on competing platforms.
What makes Condor Software unique
- Condor’s March 18, 2026 Series A from Insight Partners validates a niche biopharma wedge.
- Its October 20, 2026 investigator-grants tool automates CRO and site-payment reconciliation end-to-end.
- Condor’s March 2026 platform unifies clinical, operational, and financial data for trial finance.
Help us improve and share your feedback! Did you find this helpful?
Funding
Industry standards